The clearance allows the system to offer personalised insights for individuals managing diabetes through MDI therapies.

Objective: To assess the functionality and patient acceptability of HumaPen Ergo ®, a new 3.0ml reusable insulin pen. Design: Patients trialled HumaPen Ergo ® (Eli Lilly) over 5 to 7 weeks and ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

In an advancement for diabetes management, the US Food and Drug Administration (FDA) has granted clearance to Medtronic’s new ...

Injection Pen Market. The global injection pen market is on track for substantial growth, with a forecasted compound annual ...

Managing diabetes has come a long way, thanks to advancements in treatments and technologies that make life easier and ...

In early May 2024, the National Department of Health (NDoH) in South Africa faced a significant setback for people with ...

With a new smartphone app clearance from the FDA, Medtronic said it has all the pieces necessary to deliver a complete ...

The clearance paves the way for the launch of Medtronic’s Smart MDI system, which combines its InPen and Simplera continuous ...

The InPen app paves the way for the launch of the company’s “Smart MDI” system combining a smart insulin pen that tracks ...